doctors, patients and scans

Leading CRAC Channel Platform Company Delivering Drug Candidates For Inflammatory Diseases

About Us

CalciMedica is a leader in the discovery and development of CRAC channel inhibitor drugs. CRAC channels are expressed on many cell types, including lung endothelium cells, pancreatic acinar cells and immune system cells, where aberrant activation of these channels may play a key role in the pathobiology of acute and chronic inflammatory syndromes. The Company has a portfolio of highly selective CRAC channel inhibitor drugs that it is developing to improve outcomes for patients with acute inflammatory indications. CalciMedica’s lead compound AuxoraTM has delivered promising Phase 2 results in two indications, down-regulating cytokines and preventing organ damage in both severe COVID-19 pneumonia and predicted severe acute pancreatitis. Potential registration studies in severe COVID-19 pneumonia, flu pneumonia with respiratory failure/acute respiratory distress syndrome (ARDS) and predicted severe acute pancreatitis are scheduled to start in 2020.

CalciMedica is headquartered in San Diego, CA.

Company History

CalciMedica was founded in 2007 by Ken Stauderman, CalciMedica’s Chief Scientific Officer, along with Anjana Rao and Patrick Hogan (then at Harvard’s CBR Institute of Biomedical Research and currently at the La Jolla Institute of Immunology) and Stefan Feske (then at Harvard’s CBR Institute of Biomedical Research and currently at NYU School of Medicine). Dr. Stauderman’s work includes the discovery of STIM1, a protein that works in concert with Orai1 to form the CRAC channels targeted by CalciMedica’s drugs. At CalciMedica, Dr. Stauderman developed a series of proprietary assays that have allowed for the identification of highly selective CRAC channel inhibitors and has built a leading platform for this work. The Company has advanced two different CRAC channel inhibitors into human clinical testing, including its lead compound AuxoraTM. It has also generated a novel set of CRAC channel inhibitors with different features, and assembled a portfolio of patents and patent applications covering those compounds as well as different aspects of CRAC channel biology, including the STIM and Orai proteins that are key elements of a CRAC channel.
Nurse and Cell Image

CRAC Channel Biology

Calcium release-activated calcium (CRAC) channels are comprised of two key components – STIM and Orai proteins—that work to regulate the flow of Ca2+ into cells. CRAC channels are expressed in many cell types, including lung endothelium cells, pancreatic acinar cells and immune system cells, where they control a variety of normal cell functions. However, when a cell is under attack, for example by a virus or toxin, the CRAC channel can open excessively, leading to an imbalance of calcium and disrupting cell function. Evidence suggests that overactivated CRAC channels play a role in inflammation-induced injury of pulmonary endothelial cells, resulting in loss of alveolar-capillary barrier function and accumulation of fluid into the alveoli. Similarly, hyperactivation of CRAC channels results in excessive calcium influx in pancreatic acinar cells, which plays a pivotal role in cellular injury and the progression of acute pancreatitis. Efforts to block CRAC channels and restore healthy cell function have focused on inhibiting STIM or Orai proteins. CalciMedica’s AuxoraTM targets the Orai1 protein, thereby blocking excessive calcium entry caused by aberrant CRAC channel activity.

Pipeline

CalciMedica’s lead clinical compound, AuxoraTM, is a potent and selective small molecule inhibitor of Orai1-containing CRAC channels that is being developed for use in patients with diseases that have respiratory dysfunction, including ARDS as a major component. Such diseases include severe COVID-19 pneumonia, acute flu pneumonia with respiratory failure/ARDS, and acute pancreatitis with accompanying systemic inflammatory response syndrome (SIRS). Evidence suggests that CRAC channels play a role in inflammation-induced injury of pulmonary endothelial cells, resulting in loss of alveolar-capillary barrier function and accumulation of fluid in the alveoli. Similarly, hyperactivation of CRAC channels results in excessive calcium influx into pancreatic acinar cells and plays a pivotal role in cellular injury and the progression of acute pancreatitis. In each of these settings, local and systemic inflammation can lead to organ failure and death. Auxora has demonstrated reduced ventilator use and mortality as well as improved time to recovery in patients with severe COVID-19 pneumonia on low-flow supplemental oxygen therapy. In patients with hypoxemia secondary to SIRS from acute pancreatitis, Auxora has been found to accelerate patient recovery, decrease hospital stay and potentially protect lung and kidney function.

CalciMedica is also exploring other acute indications for Auxora such as viral pneumonia, acute lung injury (ALI), acute respiratory distress syndrome (ARDS) and acute kidney injury (AKI).

For more details on the clinical trial of Auxora in patients with severe COVID-19 pneumonia, please visit: clinicaltrials.gov.

Team

Management

The CalciMedica team is comprised of scientists, physicians, drug development experts and entrepreneurs dedicated to the development of CRAC channel inhibitors for acute and chronic inflammatory conditions.
Rachel Leheny
A. Rachel Leheny, Ph.D.
Chief Executive Officer and Chairman
Michael Dunn
Michael Dunn, MBA
President & Chief Operating Officer
Sudarshan Hebbar
Sudarshan Hebbar, M.D.
Chief Medical Officer
Kenneth Stauderman
Kenneth Stauderman, Ph.D.
Co-founder & Chief
Scientific Officer
Michael Dixon
Michael Dixon, CPA, CA
Chief Financial Officer

Board of Directors

  • Robert McNeil, Ph.D.
    Co-Chairman of the Board
  • Robert N. Wilson
    Co-Chairman of the Board
  • Eric Roberts
    Vice Chairman of the Board
  • A. Rachel Leheny, Ph.D.
    Chief Executive Officer and Chairman
  • Michael Dunn, MBA
    President & Chief Operating Officer
  • Fred Middleton, MBA
    Managing Director, Sanderling Ventures
  • Lakhmir Chawla, M.D.
    Chief Medical Officer, La Jolla Pharmaceuticals Company

News

CalciMedica and EpiPharma Enter into Research Collaboration to Discover and Develop CRAC Channel Inhibitor Therapies

Under the terms of the research collaboration agreement, CalciMedica will use EpiPharma’s state of the art Pre-clinical Drug Testing and Diagnostics Laboratory Platform to accelerate …

CalciMedica Announces Data Showing Auxora™ Substantially Improved Outcomes in Patients with Severe COVID-19 Pneumonia

Median time to recovery was more than two times faster for patients treated with Auxora plus standard of care compared to standard of care alone …

CalciMedica Appoints Robert N. Wilson as Co-Chairman of the Board of Directors and Eric W. Roberts as Vice Chairman

Robert N. Wilson was Former Johnson & Johnson Vice Chairman Board Member, Eric W. Roberts, named Vice Chairman and Chairman of the Strategic Transactions and …

CalciMedica Announces Positive Topline Data from Interim Analysis of Trial Evaluating Auxora™ in Patients with Severe COVID-19 Pneumonia

Interim results showed Auxora plus standard of care improved time to recovery and reduced ventilator use in patients compared to standard of care alone  LA …

CalciMedica Raises $15 Million in Series C Financing Round Led by Valence Life Sciences

Funds to support ongoing clinical trials in patients with COVID-19 pneumonia and commercial manufacturing of Auxora™   LA JOLLA, Calif., May 22, 2020 – CalciMedica Inc. (“CalciMedica” …

CalciMedica Announces that FDA Has Strongly Recommended Moving to a Blinded Placebo-controlled Trial with Auxora™ in Patients with Severe COVID-19 Pneumonia

LA JOLLA, Calif., May 21, 2020 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment …

CalciMedica Announces Independent Safety Review Committee Recommendation to Continue Phase 2 Study of CM4620-IE in Patients with Severe COVID-19 Pneumonia on Low-Flow Oxygen Therapy

LA JOLLA, Calif., May 7, 2020 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment …

CalciMedica Expands Clinical Study to Assess CM4620-IE in Patients with Critical COVID-19 Pneumonia on High-Flow Oxygen Therapy

Phase 2 open-label study expands to additional sites across the U.S. and aims to enroll 120 patients  LA JOLLA, Calif., April 30, 2020 – CalciMedica Inc. …

FDA Grants CalciMedica Permission to Begin Dosing CM4620-IE in Patients with Severe COVID-19 Pneumonia under a Newly Opened IND

Regions Hospital in St. Paul, Minnesota has begun a Phase 2 clinical study of CM4620-IE in patients with severe COVID-19 pneumonia this week, and Henry …

CalciMedica to Present Results of PD/PK Study in Acute Pancreatitis Patients for Its CRAC Channel Inhibitor CM4620 at APA Annual Meeting

LA JOLLA, CA, November 7, 2019 /PRNewswire/ — Kenneth Stauderman, Ph.D., CalciMedica’s Chief Scientific Officer, is presenting a poster at the American Pancreas Association annual …

Henry Ford Hospital Physician Presents Results from the Initial Patient Study of CalciMedica’s CRAC Channel Inhibitor CM4620 in Acute Pancreatitis at ACEP Meeting

LA JOLLA, CA, October 30, 2019 /PRNewswire/ — Joseph Miller, MD, MS, a physician at the Henry Ford Health System in Detroit, MI, and a …

CalciMedica Names Life Science Veteran to Its Board of Directors

LA JOLLA, CA, March 26, 2019 /PRNewswire/ — CalciMedica, a clinical-stage biopharmaceutical company developing CM4620, a novel small molecule compound for acute pancreatitis, announced that …

CalciMedica, Inc. to Present Study Population Profile from Its Initial Patient Study of Its CRAC Channel Inhibitor CM4620 in Acute Pancreatitis at International Conference

LA JOLLA, CA, March 19, 2019 /PRNewswire/ — Physicians from several study sites involved in CalciMedica’s initial acute pancreatitis clinical study of its CRAC channel …

CalciMedica Names Two Senior Executives to Its Board of Directors

LA JOLLA, CA, May 1, 2018 /PRNewswire/ — CalciMedica announced that it named two independent members to its Board of Directors, Lakhmir Chawla, MD, currently …

Research Collaboration Between the San Francisco VA, UCSF and CalciMedica, Inc. to Present Results on CRAC Channel Inhibitors in a Stroke Model at International Conference

LA JOLLA, CA, January 24, 2018 /PRNewswire/ — Researchers from the San Francisco Veterans Affairs Medical Center and UCSF, and CalciMedica, Inc., are presenting a …

Contact Us

Media contact:

Karen O’Shea, Ph.D.
LifeSci Communications
koshea@lifescicomms.com

Scroll to Top